Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 10:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fluzone Standard Dose Inactivated Influenza Vaccine Clear all
Completed Phase 2 Interventional

Influenza Vaccination in Patients Receiving Antineoplastic Therapy for Non-Hodgkin's Lymphoma

NCT00307710
View directory record Official record
Conditions
Lymphoma
Interventions
Trivalent Baculovirus-expressed Influenza HA vaccine
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Sep 30, 2026, 10:03 PM EDT
Completed Phase 4 Interventional Results available

Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.

NCT01808456
View directory record Official record
Conditions
Influenza, Human, Transplantation Infection
Interventions
influenza trivalent inactive vaccine, influenza trivalent inactive vaccine high dose
Biological
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Sep 30, 2026, 10:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring

NCT04460781
View directory record Official record
Conditions
Influenza
Interventions
Flublok Quadrivalent influenza vaccine RIV4, Standard-dose quadrivalent inactivated influenza vaccine SD-IIV4
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
Up to 64 Years
Enrollment
96,175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Sep 30, 2026, 10:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects

NCT00388583
View directory record Official record
Conditions
Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions
Split, Inactivated, Trivalent Influenza Vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
65 Years and older
Enrollment
817 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
17
States / cities
Alabaster, Alabama • Tucson, Arizona • Fountain Valley, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Sep 30, 2026, 10:03 PM EDT
Completed Phase 2 Interventional Results available

High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients

NCT03179761
View directory record Official record
Conditions
Hematopoietic Cell Transplantation
Interventions
Quadrivalent Inactivated Influenza Vaccine, Laboratory Biomarker Analysis, Trivalent Influenza Vaccine
Biological · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • Chicago, Illinois • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Sep 30, 2026, 10:03 PM EDT
Completed Phase 1 Interventional

Standard Dose Versus High-Dose Inactivated Flu Vaccine in Pediatric Solid Organ Transplant Patients

NCT01525004
View directory record Official record
Conditions
Pediatric Solid Organ Transplant Patients
Interventions
High-Dose trivalent inactivated influenza vaccine, Standard dose trivalent inactivated influenza vaccine
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
3 Years to 17 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced Sep 30, 2026, 10:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Elderly Influenza Vaccine Immunogenicity Substudy

NCT00170482
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Sep 30, 2026, 10:03 PM EDT
Recruiting Phase 2 Interventional

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients

NCT05947071
View directory record Official record
Conditions
Immunization; Infection, Transplantation Infection, Influenza
Interventions
Standard Dose Quadrivalent Inactivated Influenza Vaccine, High Dose Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 17 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
10
States / cities
Stanford, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 30, 2026, 10:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects

NCT00551031
View directory record Official record
Conditions
Influenza, Myxovirus Infection
Interventions
Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1), Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2), Split, Inactivated, Trivalent Influenza Vaccine (Standard dose), Split, Inactivated, Trivalent Influenza Vaccine (High-dose)
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
2,098 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
29
States / cities
Alabaster, Alabama • Mobile, Alabama • Chandler, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Sep 30, 2026, 10:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Simultaneous mRNA COVID-19 and IIV4 Vaccination Study

NCT05028361
View directory record Official record
Conditions
Quality of Life, Injection Site Reaction, Adverse Drug Event, Systemic Reaction
Interventions
mRNA COVID-19, IIV4, Placebo (saline)
Biological · Other
Lead sponsor
Duke University
Other
Eligibility
5 Years and older
Enrollment
348 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
Baltimore, Maryland • Durham, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 30, 2026, 10:03 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age

NCT06641180
View directory record Official record
Conditions
Influenza
Interventions
High-Dose trivalent influenza vaccine (Split virion, Inactivated), Standard-dose trivalent influenza vaccine (Split virion, Inactivated)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
50 Years to 64 Years
Enrollment
1,180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
20
States / cities
Los Alamitos, California • Fort Myers, Florida • Hollywood, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 30, 2026, 10:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults

NCT05874713
View directory record Official record
Conditions
Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
Interventions
aH5N8c on Day 1, aH5N6c on Day 1, aH5N8c on Day 22, aH5N6c on Day 22, aH5N8c on Day 202
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
9
States / cities
Cullman, Alabama • Lilburn, Georgia • Norcross, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Sep 30, 2026, 10:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Eldery High Dose TIV 2005

NCT00115531
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years and older
Enrollment
414 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
5
States / cities
Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Sep 30, 2026, 10:03 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults

NCT00772109
View directory record Official record
Conditions
Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions
Influenza Virus Vaccine USP Trivalent Types A and B
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
4,292 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
46
States / cities
Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Sep 30, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Results available

Standard Versus High-Dose Trivalent Inactivated Flu Vaccine in Pediatric Acute Lymphoblastic Leukemia Patients

NCT01216332
View directory record Official record
Conditions
Pediatric Patients With Acute Lymphoblastic Leukemia
Interventions
High-dose trivalent inactivated influenza vaccine, Standard dose trivalent inactivated influenza vaccine
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
3 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Sep 30, 2026, 10:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Immunogenicity and Safety of Different Doses of Fluzone® Influenza

NCT00253734
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® (IM), Fluzone®
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Sep 30, 2026, 10:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults

NCT03743688
View directory record Official record
Conditions
Influenza, Influenza, Human, Vaccine Reaction, Influenza A, Influenza Type B, Influenza A H1N1, Influenza A H3N2
Interventions
Influenza Vaccine Recipients
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Sep 30, 2026, 10:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study of Immune Responses to Influenza Vaccination

NCT03346772
View directory record Official record
Conditions
Influenza Vaccination
Interventions
Influenza vaccination
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 30, 2026, 10:03 PM EDT
Withdrawn Phase 2 Interventional

High Dose Influenza in Immunosuppressed Subjects

NCT00766285
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine, Trivalent Baculovirus-expressed Influenza HA vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced Sep 30, 2026, 10:03 PM EDT
Active, not recruiting Phase 2 Interventional

High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

NCT05215327
View directory record Official record
Conditions
Immunization; Infection, Transplantation Infection, Influenza
Interventions
High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
16 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Sep 30, 2026, 10:03 PM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly

NCT01623232
View directory record Official record
Conditions
Influenza Vaccines, Aged
Interventions
MAS-1 adjuvant and influenza HA antigen, standard dose, inactivated trivalent influenza vaccine (TIV)
Biological
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
65 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
4
States / cities
Palo Alto, California • Iowa City, Iowa • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2012 · Synced Sep 30, 2026, 10:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding Women

NCT01181323
View directory record Official record
Conditions
Influenza
Interventions
Placebo, Cold-adapted live attenuated influenza virus vaccine, trivalent, Trivalent inactivated influenza vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years · Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Sep 30, 2026, 10:03 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly

NCT00391053
View directory record Official record
Conditions
Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions
High-Dose Inactivated, Split-Virion Influenza Vaccine, Inactivated, Split-Virion Influenza Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
3,851 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
28
States / cities
Mesa, Arizona • Phoenix, Arizona • Tempe, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Sep 30, 2026, 10:03 PM EDT
Completed Phase 2 Interventional Results available

Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults

NCT01685372
View directory record Official record
Conditions
Solid Organ Transplant Recipient (Liver, Kidney, Heart), Rheumatologic Disorder, Human Immunodeficiency Virus (HIV), Bone Marrow Transplant (BMT), Dialysis
Interventions
Fluzone High Dose, Fluzone
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
5 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 30, 2026, 10:03 PM EDT